Skip to main content

Table 1 Genes preferentially expressed on chemotherapy-resistant AML relapse

From: LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro

Genes identified

Primary differential screening mRNA expression

Individual patients means of mRNA expression

 

R/L

R/L

H/L

Novel

   

ARAP

5.0

40.

0.9

Transcription factors

   

LEDGF/p75

4.8

7.7

2.8

ERF-2/TS11d

2.2

3.3

1.3

Translation-related

   

EF-1

3.2

3.2

3.4

rpL3

2.9

  

rpL6

4.5

2.8

4.7

rpL11

2.7

  

rpL34

2.7

  

rpL41

3.6

  

rpS4

5.3

3.8

3.5

rpS12

3.2

  

rpS24

2.7

  

rpS25

2.7

  

Mitochondria-related

   

CytOX II

2.4

2.1

2.5

CytOX III

4.0

2.3

3.7

ND4

2.7

  

Others

   

Lysozyme

4.2

2.3

4.1

MHC-DRA

3.6

  

PSME1/pAI

2.4

  
  1. The results are based on primary differential screening of an AML cDNA library of more than 25,000 colonies. Probing was with cDNa probes derived from RNA of pooled native AML blasts from either patients sensitive to chemotherapy or from patients relapsing after several chemotherapy treatment courses. It also shows the means of mRNA expression in relapsed AML blasts relative to sensitive blasts from individual patients. [32P] cDNA derived from individual AML patient blasts (L1-3, R1-5 and H1-5) were used as probes for dot-blot analysis against nine of the genes found up-regulated in pooled RNA from resistant AML blasts. Only genes with expression ratio exceeding 2 are presented. L: low risk blasts; H, high risk blasts; ARAP, AML resistance associated protein; rp, ribosomal protein; CytOX II, III, cytochrome C oxidase subunit II and III; ND4, NADH dehydrogenase subunit 4; EF-1, elongation factor 1; PSME1/pAI, proteasome activator 28 subunit I; ERF-2/TIS11d, EGF response factor-2/human homolog of TIS11d; LEDGF, lens epithelium derived growth factor, and MHC-DRA, major histocompatibility complex class II DR alpha.